Vergelijking

CagriSema vs. Pemvidutide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	CagriSema	Pemvidutide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

CagriSema

Volledige vermelding →

Pemvidutide

Volledige vermelding →

Frequently asked questions

What is the difference between CagriSema and Pemvidutide?: CagriSema is classified as "Metabool", while Pemvidutide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Pemvidutide?: The highest available evidence level is "Humane RCT" for CagriSema and "Humane studie" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Pemvidutide in Germany and the United States?: Duitsland: CagriSema — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Pemvidutide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between CagriSema and Pemvidutide?

CagriSema is classified as "Metabool", while Pemvidutide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Pemvidutide?

The highest available evidence level is "Humane RCT" for CagriSema and "Humane studie" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Pemvidutide in Germany and the United States?

Duitsland: CagriSema — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.